Biohaven Pharmaceutical Holding Company Ltd , a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States.
infoBiohaven Pharmaceutical Holding Company is a small cap stock with a total market cap of 1.35B.
infoThey trade on the NYSE and had their IPO 11 months ago.
infoBiohaven Pharmaceutical Holding Company currently employs 928 people.
infoAs of Wednesday, Aug 23 2023, Biohaven Pharmaceutical Holding Company’s share price is $19.77.
News Relating to Biohaven Pharmaceutical Holding Company
The Motley Fool
Why Biohaven Stock Is Crashing Today
Thursday Jul 27 2023 at 12:50
The FDA refused to review Biohaven’s filing for approval of troriluzole in treating an ultrarare disease. Biohaven still hopes to convince the agency of the merits of its data on the experimental drug.
The Motley Fool
2 Growth Stocks With Major Incoming Catalysts
Tuesday Jun 27 2023 at 05:31
BridgeBio stock collapsed when acoramidis failed a pivotal trial, but follow-up data on the way could allow the program, and the stock, to redeem itself. Biohaven shares could shoot higher if the U.S. Food and Drug Administration accepts the company’s latest new drug application.
The Motley Fool
Why Biohaven Stock Caught Fire This Week
Friday Jun 02 2023 at 09:11
Wednesday, Biohaven held a research and development day presentation for investors. With the company making progress on several fronts, investors appear to be optimistic about its post-buyout future.
Zacks Investment Research
Biohaven (BHVN) Stock up 8% on Encouraging Pipeline Updates
Thursday Jun 01 2023 at 12:36
At its R&D Day, Biohaven (BHVN) provides updates on its pipeline. It also announced submission of a regulatory filing seeking approval for troriluzole in SCA3, an ultra-rare disorder.
Zacks Investment Research
Is Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year?
Thursday Mar 30 2023 at 11:23
Here is how Biohaven Ltd. (BHVN) and Hologic (HOLX) have performed compared to their sector so far this year.
Zacks Investment Research
Biohaven (BHVN) Acquires Dual Inhibitor for Brain Disorders
Thursday Mar 23 2023 at 12:13
Biohaven (BHVN) has acquired an exclusive license for dual Inhibitor of TYK2/JAK1 for the pre-clinical study of immune-mediated brain disorders.
Seeking Alpha
Biohaven: Spun And Done – Time To Exit
Thursday Mar 09 2023 at 17:06
Biohaven is on the far side of its spin cycle and faces the world as a much diminished company. Biohaven has upcoming catalysts, but they are either early stage or have serious question marks.
Investors Business Daily
Here’s What’s Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
Thursday Feb 02 2023 at 12:52
Biohaven is taking the same tact that led to a nearly $12 billion Pfizer buyout with the rest of its pipeline — and BHVN stock has soared. The post Here’s What’s Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric appeared first on Investor’s Business Daily.
24/7 Wall Street
These Are the Top 10 Holdings of Paul Tudor Jones
Tuesday Jan 10 2023 at 22:55
Paul Tudor Jones is one of the most respected names in the hedge fund industry.
PRNewsWire
Biohaven to Present at the 41st Annual J.P. Morgan Healthcare Conference
Friday Jan 06 2023 at 07:30
NEW HAVEN, Conn. , Jan. 6, 2023 /PRNewswire/ — Biohaven Ltd.
Zacks Investment Research
Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?
Thursday Jan 05 2023 at 11:17
Here is how Biohaven Ltd. (BHVN) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
Zacks Investment Research
After Plunging 13% in 4 Weeks, Here’s Why the Trend Might Reverse for Biohaven Ltd. (BHVN)
Tuesday Nov 29 2022 at 11:17
Biohaven Ltd. (BHVN) is technically in oversold territory now, so the heavy selling pressure might have exhausted.
CNBC Television
Biohaven CEO on ‘monumental approval’ of migraine drug
Saturday Nov 19 2022 at 05:40
“We can now say you know that Nurtec ODT is approved for the preventative treatment of migraine,” Biohaven CEO Vlad Coric said.
Zacks Investment Research
Biohaven Ltd. (BHVN) Surges 7.6%: Is This an Indication of Further Gains?
Friday Oct 07 2022 at 04:31
Biohaven Ltd. (BHVN) witnessed a jump in share price last session on above-average trading volume.
Seeking Alpha
Biohaven Stub May Provide An Interesting Setup For Investors
Thursday Oct 06 2022 at 22:11
Biohaven’s most valuable migraine-related assets were recently acquired by Pfizer for $11.6 billion. This has left a far smaller stub of cash and other pharmaceutical assets now trading as Biohaven that may be worth around $24/share, well above the current price.
Zacks Investment Research
Biohaven (BHVN) Stock Up on Spin-Off Transaction Finalization
Thursday Oct 06 2022 at 12:02
The newly spun-off Biohaven Ltd. (BHVN) advances a portfolio of non-CGRP pipelines targeting neurological and neuropsychiatric indications.
The Motley Fool
Why Biohaven Stock Skyrocketed Again Today
Wednesday Oct 05 2022 at 16:45
The “new” Biohaven is enjoying plenty of attention from investors.
CNBC Television
Biohaven CEO on on Pfizer’s acquisition of the company
Tuesday Oct 04 2022 at 19:27
Cramer spoke with Biohaven CEO Vlad Coric on Tuesday.
The Motley Fool
Why Biohaven Stock Is Soaring Today
Tuesday Oct 04 2022 at 12:29
The “old” Biohaven is gone, leaving the “new” Biohaven to rise.
Biohaven Pharmaceutical Holding Company Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Biohaven Pharmaceutical Holding Company’s Altman Z-score is 1.9 which is in the gray zone. This indicates a level of ambiguity where further analyses are needed to evaluate the company’s financial stability accurately.
Derived from SEC.GOV filing dataopen_in_new
Biohaven Pharmaceutical Holding Company Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 1 insider has bought $1.98M of common stock in Biohaven Pharmaceutical Holding Company on the stock market with no insider selling.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Biohaven Pharmaceutical Holding Company’s Income Quality of 0.68 is in line with its Industry Group of 0.69 (-1.4% lower)
Biohaven Pharmaceutical Holding Company’s Income Quality of 0.68 is in line with its Major Industry Group of 0.71 (-4.2% lower)
Biohaven Pharmaceutical Holding Company’s Income Quality of 0.68 is in line with its Sector of 0.75 (-9.3% lower)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Biohaven Pharmaceutical Holding Company’s Current Ratio of 4.94 is in line with its Industry Group of 4.76 (3.8% greater)
Biohaven Pharmaceutical Holding Company’s Current Ratio of 4.94 is greater than its Major Industry Group of 4.32 (14.4% greater)
Biohaven Pharmaceutical Holding Company’s Current Ratio of 4.94 is greater than its Sector of 2.6 (90.0% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-3.14 & -1.27)
Cannot compare a negative PE Ratio (-3.14 & -1.1)
Cannot compare a negative PE Ratio (-3.14 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Biohaven Pharmaceutical Holding Company’s PB Ratio of 3.49 is greater than its Industry Group of 1.34 (160.4% greater)
Biohaven Pharmaceutical Holding Company’s PB Ratio of 3.49 is greater than its Major Industry Group of 1.4 (149.3% greater)
Biohaven Pharmaceutical Holding Company’s PB Ratio of 3.49 is greater than its Sector of 1.62 (115.4% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Biohaven Pharmaceutical Holding Company’s ROE of -1.11 is lower than its Industry Group of -0.44 (-152.3% lower)
Biohaven Pharmaceutical Holding Company’s ROE of -1.11 is lower than its Major Industry Group of -0.38 (-192.1% lower)
Biohaven Pharmaceutical Holding Company’s ROE of -1.11 is lower than its Sector of -0.03 (-3600.0% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Biohaven Pharmaceutical Holding Company’s ROCE of -1.08 is lower than its Industry Group of -0.42 (-157.1% lower)
Biohaven Pharmaceutical Holding Company’s ROCE of -1.08 is lower than its Major Industry Group of -0.37 (-191.9% lower)
Biohaven Pharmaceutical Holding Company’s ROCE of -1.08 is lower than its Sector of -0.04 (-2600.0% lower)
Derived from SEC.GOV filing dataopen_in_new